Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$29 Mln
P/E Ratio
--
P/B Ratio
0.48
Industry P/E
--
Debt to Equity
-0.29
ROE
-4.16 %
ROCE
-317.63 %
Div. Yield
0 %
Book Value
--
EPS
-21.87
CFO
$-401.13 Mln
EBITDA
$-461.43 Mln
Net Profit
$-486.80 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aligos Therapeutics Inc (ALGS)
| -86.55 | -50.14 | -83.69 | -73.23 | -46.50 | -- | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Aligos Therapeutics Inc (ALGS)
| 138.29 | -30.32 | -91.97 | -57.07 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that... is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Address: One Corporate Drive, South San Francisco, CA, United States, 94080 Read more
CEO, President & Chairman of the Board
Dr. Lawrence M. Blatt MBA, Ph.D.
CEO, President & Chairman of the Board
Dr. Lawrence M. Blatt MBA, Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aligos Therapeutics Inc (ALGS) stood at $ 70 Mln as on 31-Dec-24
The share price of Aligos Therapeutics Inc (ALGS) is $5.44 (NASDAQ) as of 23-Apr-2025 16:27 EDT. Aligos Therapeutics Inc (ALGS) has given a return of -46.5% in the last 3 years.
Aligos Therapeutics Inc (ALGS) has a market capitalisation of $ 29 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aligos Therapeutics Inc (ALGS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aligos Therapeutics Inc (ALGS) and enter the required number of quantities and click on buy to purchase the shares of Aligos Therapeutics Inc (ALGS).
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Address: One Corporate Drive, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Lawrence M. Blatt MBA, Ph.D.. is Aligos Therapeutics Inc (ALGS), and CFO & Sr. VP is Dr. Lawrence M. Blatt MBA, Ph.D..
There is no promoter pledging in Aligos Therapeutics Inc (ALGS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Aligos Therapeutics Inc (ALGS) | Ratios |
|---|---|
|
Return on equity(%)
|
-415.84
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-3326.01
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aligos Therapeutics Inc (ALGS) was $0 Mln.
$0.30
(
